Nov 17, 2021 4:33 pm EST CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Nov 15, 2021 8:00 am EST CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC
Nov 11, 2021 8:00 am EST CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
Nov 10, 2021 4:06 pm EST CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
Nov 03, 2021 4:05 pm EDT CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
Aug 12, 2021 4:06 pm EDT CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
Aug 05, 2021 4:01 pm EDT CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021